Recent Quotes
My Watchlist
Indicators
Local Stocks
NewsOK Local Stocks
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Quanterix Corp (NQ: QTRX )

18.79 -0.72 (-3.69%)
Streaming Delayed Price Updated: 4:00 PM EDT, Jun 24, 2022 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 2,039,408
Open 19.65
Bid (Size) 16.10 (15)
Ask (Size) 25.80 (6)
Prev. Close 19.51
Today's Range 18.73 - 20.09
52wk Range 14.58 - 66.21
Shares Outstanding 36,910,137
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year

Top News

More News
Quanterix's Return On Capital Employed Overview
According to Benzinga Pro data, during Q1, Quanterix (NASDAQ:QTRX) posted sales of $29.55 million. Earnings were up 9.35%, but Quanterix still reported an overall loss of $18.15 million. 
Via Benzinga
Quanterix to Participate in Goldman Sachs 43rd Annual Global Healthcare Conference
From Quanterix Corporation
Via Business Wire

Performance

YTD
-55.69%
-55.69%
1 Month
+4.74%
+4.74%
3 Month
-31.90%
-31.90%
6 Month
-55.27%
-55.27%
1 Year
-71.39%
-71.39%

More News

Read More
Quanterix Announces Appointment of Karen A. Flynn to Board of Directors
From Quanterix Corporation
Via Business Wire
Quanterix Corporation Releases Operating Results for First Quarter 2022
From Quanterix Corporation
Via Business Wire
Recap: Quanterix Q4 Earnings
Via Benzinga
Earnings Scheduled For March 1, 2022
Via Benzinga
Earnings Scheduled For May 10, 2022
Via Benzinga
Earnings Preview For Quanterix
Via Benzinga
Quanterix Corporation to Release First Quarter 2022 Financial Results on May 10, 2022
From Quanterix Corporation
Via Business Wire
Quanterix Receives FDA Breakthrough Device Tag For NfL Test For Multiple Sclerosis
Via Benzinga
Quanterix Granted Breakthrough Device Designation from U.S. FDA for NfL Test for Multiple Sclerosis
From Quanterix Corporation
Via Business Wire
What 4 Analyst Ratings Have To Say About Quanterix
Via Benzinga
Quanterix’ Simoa® Technology Powers Large, International Comprehensive Reference Range Study Utilizing Serum Neurofilament Light (sNfL) to Assess Disease Activity in Multiple Sclerosis (MS) Patients
From Quanterix Corporation
Via Business Wire
Quanterix's Return On Capital Employed Insights
Via Benzinga
Quanterix Corporation to Release Fourth Quarter and Full Year 2021 Financial Results on March 1, 2022
From Quanterix Corporation
Via Business Wire
Quanterix Receives Funding from the Alzheimer’s Drug Discovery Foundation to Accelerate Alzheimer’s Disease Diagnostic Plasma Test Development
From Quanterix Corporation
Via Business Wire
Quanterix to Participate in the SVB Leerink Global Healthcare Conference
From Quanterix Corporation
Via Business Wire
Stocks That Hit 52-Week Lows On Tuesday
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For March 2, 2022
Via Benzinga
UK Dementia Research Institute Biomarker Factory Powers Alzheimer’s Disease Breakthroughs with Quanterix Simoa® Technology
From Quanterix Corporation
Via Business Wire
Quanterix’ Simoa® Technology Powers Latest Breakthrough in Epstein-Barr Virus and Multiple Sclerosis
From Quanterix
Via Business Wire
Quanterix Provides Operational and Preliminary Financial Highlights
From Quanterix Corporation
Via Business Wire
Quanterix to Present at 40th Annual J.P. Morgan Healthcare Conference
From Quanterix Corporation
Via Business Wire
Quanterix Recognized as a Fastest-Growing Company in North America on the 2021 Deloitte Technology Fast 500™
From Quanterix Corporation
Via Business Wire
Quanterix’ Simoa® Technology Powers Advances in Alzheimer’s Disease Research Presented at 2021 Clinical Trials on Alzheimer’s Disease (CTAD) Conference
From Quanterix Corporation
Via Business Wire
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.